These guidelines include:
- General information about the Life Saving Drugs Program (LSDP)
- Treatment of perinatal- and infantile-onset HPP through the LSDP
- Drugs currently available for the treatment of perinatal- and infantile-onset HPP through the LSDP
- Dosage
- General, initial and ongoing eligibility requirements
- LSDP funding conditions
- Exclusion criteria.
Life Saving Drugs Program – Perinatal- or infantile-onset hypophosphatasia (HPP) – Guidelines
About this resource
Publication date:
Publication type:
Guideline
Audience:
General public
Language:
English